CCR4 and cancer: Importantly, SFN and DIM reversed many of the cancer-associated methylation alterations, including aberrantly methylated genes that are dysregulated or are highly involved in cancer progression, such as C–C chemokine receptor type 4 (CCR4), transforming growth factor-β1 receptor type I (TGFBR1), cysteine-rich angiogenic inducer 61 (CYR61), and C-X-C chemokine receptor type 4 (CXCR4).